期刊
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
卷 12, 期 6, 页码 522-529出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-017-0417-7
关键词
CRISPR-Cas9; TALEN; Zinc-finger nucleases; Adoptive cell therapy; Chimeric antigen receptor T cells (CART); Immunotherapy; PD-1; Gene-editing
资金
- SITC (EMD-Serono Cancer Immunotherapy Clinical Fellowship)
- AACR (Bristol-Myers Squibb Oncology Fellowship in Clinical Cancer Research)
- Gabrielle's Angel Foundation
- SIES-AIL
- ASH Scholar Award
- NCI [K99 CA212302-01A1]
In this review, we discuss the most recent developments in gene-editing technology and discuss their application to adoptive T cell immunotherapy. Engineered T cell therapies targeting cancer antigens have demonstrated significant efficacy in specific patient populations. Most impressively, CD19-directed chimeric antigen receptor T cells (CART19) have led to impressive responses in patients with B-cell leukemia and lymphoma. CTL019, or KYMRIAH (TM) (tisagenlecleucel), a CD19 CAR T cell product developed by Novartis and the University of Pennsylvania, was recently approved for clinical use by the Food and Drug Administration, representing a landmark in the application of adoptive T cell therapies. As CART19 enters routine clinical use, improving the efficacy of this exciting platform is the next step in broader application. Novel gene-editing technologies like CRISPR-Cas9 allow facile editing of specific genes within the genome, generating a powerful platform to further optimize the activity of engineered T cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据